Posts

Global Cell Culture Market Growing at a CAGR of Over 10% Between 2017 and 2025

Image
In this report, the Global Cell Culture Market is valued at USD 11,210.7 million in 2015 and growing at a CAGR of over 10% between 2017 and 2025. Increasing R&D activities of healthcare, biological, and stem cell applications has enhanced the demand of molecular biological activities which is further projected to persist a vibrant aspect for market growth. Cell culture technology includes several complications including raw material supply and fully traceable botanical extracts. Rising growth in the number of regulatory approvals for cell culture-based vaccines and increasing funding for cell-based research will also influenced the market positively. Furthermore, growing application of single-use technologies and rising demand for mAbs are few factor projected to spur the market growth. Though, extensive cost involvement in cell culture research, lack of awareness for diagnosis technologies, and high contamination risks may hinder the market growth. Request

Lupus Nephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape

Image
Introduction Lupus Nephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Lupus Nephritis . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.  Global API Manufacturers of Marketed Products for Lupus Nephritis   Coverage of API manufacturers for Lupus Nephritis marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location. Get a Free Sample Report @ https://www.jsbmarketresearch.com/sample-request/lupus-nephritis-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2018 Emerging Phase III products for Lupus Nephritis  This report provides a comprehensive understanding of the emerging Phase III therapies for Lupus Nephritis whic